
TENOFOVIR DISOPROXIL FUMARATE 300 mg + EMTRICITABINE 200 mg (Tenvir EM) is a prescription combination antiviral medicine used to treat human immunodeficiency virus type 1 (HIV-1) infection as part of combination antiretroviral therapy. It may also be used for pre-exposure prophylaxis (PrEP) to help reduce the risk of acquiring HIV in eligible individuals. The medicine contains two nucleoside and nucleotide reverse transcriptase inhibitors that work together to suppress HIV replication.
| Generic name | TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE |
| Strength | 300 mg + 200 mg |
| Manufacturer | Cipla |
| Package size | 30 Tablets |
| Used for | (HIV-1) infection |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Tenofovir disoproxil fumarate and emtricitabine work by blocking the reverse transcriptase enzyme that HIV needs to copy its genetic material. By preventing the virus from producing new copies of itself, these medicines reduce the viral load, help protect the immune system, and lower the risk of acquiring HIV when used correctly for PrEP.
Dr. Dhruv Patel is a qualified medical practitioner with a clinical interest in HIV care and long-term antiretroviral therapy. He helps patients understand how antiretroviral medicines control HIV and why consistent treatment is essential for maintaining viral suppression.